Case Type: Mergers & Acquisitions

We are investigating the Board of Directors of Ellie Mae, Inc. (NasdaqGM: ELLI) regarding its sale to EM Eagle Purchaser, LLC. for $99.00 per each share of Ellie Mae Stock.

We are investigating the Board of Directors of CAS Medical Systems, Inc. (NasdaqGS: CASM) regarding its sale to Edwards Lifesciences Holding, Inc. for $2.45 per each share of CAS Medical Systems.

We are investigating The Ultimate Software Group, Inc. (NYSE: ULTI) regarding its sale to Unite Parent Corp. for $331.50 per each share of Ultimate Software.

We are investigating the Board of Directors of SunTrust Banks, Inc. (NYSE: STI) regarding its sale to BB&T Corporation (“BB&T”) for 1.295 shares of BB&T for each share of SunTrust owned.

We are investigating the Board of Directors of Multi-Color Corporation (NYSE: LABL) regarding its sale to W/S Packaging Holdings, Inc. for $50.00 per each share of Multi-Color Corporation.

We are investigating the Board of Directors of Maxwell Technologies, Inc. (Nasdaq: MXWL) regarding its sale to Tesla, Inc. (“Tesla”) for a fraction of Tesla stock equal to the quotient obtained by dividing $4.75 by the closing sale price of one (1) share of Tesla Common Stock as reported on the NASDAQ Global Select Market … Read more

We are investigating the Board of Directors of MYnd Analytics, Inc. (NasdaqCM: MYND) related to the sale of the company to Emmaus Life Sciences, Inc. Under the terms of the proposed transaction, MYND stockholders will own 5.9% of the combined company upon completion of the transaction.

We are investigating the Board of Directors of Black Ridge Acquisition Corp. (NasdaqCM: BRAC) related to the sale of Black Ridge to Allied Esports International, Inc. and affiliates. Under the terms of the proposed transaction, Black Ridge will issue to the former owners of Allied Esports and WPT Enterprises, Inc. (i) an aggregate of 11,602,754 … Read more

We are investigating Vital Therapies, Inc. (NasdaqGS: VTL) and its Board of Directors for potential federal law violations and/or breaches of fiduciary duties in connection with the acquisition of Immunic AG for approximately 735 shares of Vital Therapies common stock for each share of Immunic.

We are investigating the Board of Directors of Flex Pharma, Inc. (NasdaqCM: FLKS) related to the sale of the company to Salarius Pharmaceuticals, LLC. Under the terms of the proposed transaction, FLKS stockholders will own 19.9% of the combined company upon completion of the transaction.